Prime editing can efficiently rewrite the genetic mutation causing sickle cell disease, in haematopoietic stem cells from patients.
This is a preview of subscription content, log in via an institution to check access.
References
Everette, K. A. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01026-0 (2023).
Anzalone, A. V. et al. Nature 576, 149–157 (2019).
Newby, G. A. et al. Nature 595, 295–302 (2021).
Nelson, J. W. et al. Nat. Biotechnol. 40, 402–410 (2021); author correction 40, 432 (2022).
Chen, P. J. et al. Cell 184, 5635–5652.e29 (2021).
DeWitt, M. A. et al. Sci. Transl Med. 8, 360ra134 (2016).
Kim, D. Y., Moon, S. B., Ko, J.-H., Kim, Y.-S. & Kim, D. Nucleic Acids Res. 48, 10576–10589 (2020).
Zeng, J. et al. Nat. Med. 26, 535–541 (2020).
Frangoul, H. et al. N. Engl. J. Med. 384, 252–260 (2021).
Magnani, A. et al. Haematologica 105, 1240–1247 (2020).
Yao, S. Graphite Bio announces voluntary pause of phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (Graphite Bio, 5 January 2023); https://go.nature.com/3MZNnnA
Levesque, S. et al. Nat. Commun. 13, 5909 (2022).
Anzalone, A. V. et al. Nat. Biotechnol. 40, 731–740 (2022).
Yarnall, M. T. N. et al. Nat. Biotechnol. 41, 500–512 (2022).
Li, C. et al. Blood https://doi.org/10.1182/blood.2022018252 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Levesque, S., Bauer, D.E. Gene correction for sickle cell disease hits its prime. Nat. Biomed. Eng 7, 605–606 (2023). https://doi.org/10.1038/s41551-023-01040-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-023-01040-2
- Springer Nature Limited